Tech Company M&A Transactions
Asklepios BioPharmaceutical Acquisition
Asklepios BioPharmaceutical was purchased by Bayer AG. The transaction occurred on 10/26/2020. The transaction price was $4 billion.
Transaction Overview
Company Name
Acquired By
Announced On
10/26/2020
Transaction Type
M&A
Amount
$4,000,000,000
M&A Terms
Bayer will pay an upfront consideration of USD 2 billion and potential success-based milestone payments of up to USD 2 billion.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
20 T.W. Alexander 110
Research Triangle Park, NC 27709
USA
Research Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
Asklepios BioPharmaceutical, Inc. (AskBio) is a privately held AAV gene therapy based company founded in 2001 to advance the work of Dr. Richard Jude Samulski, former Director of the Gene Therapy Center at the University of North Carolina (UNC) from the lab into the clinic. Dr. Samulski was the first to clone AAV for therapeutic purposes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sheila Mikhail
Chief Medical Officer
Martin Childers
Chief Operating Officer
Robert King
Chief Scientific Officer
Philippe Moullier
Chief Technical Officer
Josh Grieger
Co-Founder
Richard Samulski
VP - Regulatory Affairs
Diane Balderson
Browse more venture capital transactions:
Prev: 10/26/2020: Linktree venture capital transaction
Next: 10/27/2020: KETOS venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs